| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536928 | Vaccine | 2017 | 8 Pages |
Abstract
Post-treatment adjuvant qHPV vaccination in HIV-infected MSM aged 27 or above is likely to be cost-effective. Use of adjuvant qHPV vaccination could be considered as a potential strategy to reduce rising anal cancer burden among these high-risk individuals.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ashish A. Deshmukh, Scott B. Cantor, Elisabeth Fenwick, Elizabeth Y. Chiao, Alan G. Nyitray, Elizabeth A. Stier, Stephen E. Goldstone, Timothy Wilkin, Jagpreet Chhatwal,